Drilldown: Medicines

Amantadine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Butorphanol (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Clozapine (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Entacapone (1) · Ethylmorphine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Levodopa (1) · Levorphanol (1) · Meperidine (1) · Nalbuphine (1) · Opicapone (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Tapentadol (1) · Tolcapone (1) · Trihexyphenidyl (1)

None (6) · (multiple, generic dominant) (1) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Clozaril (Novartis, original brand; 25 mg and 100 mg tablets); FazaClo (orally disintegrating tablets, 12.5/25/100/150/200 mg); Versacloz (oral suspension 50 mg/mL); multiple generics. All clozapine products are subject to the same REMS monitoring requirements. (1) · Cogentin (1) · Comtan (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dostinex (1) · Duragesic (1) · Eldepryl (1) · Neupro (1) · Nubain (1) · Nucynta (1) · Ongentys (1) · Opana (1) · Parlodel (1) · Sinemet (1) · Stadol (1) · Symmetrel (1) · Talwin (1) · Tasmar (1) · Vicodin (1) · Xadago (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective M1 muscarinic antagonist (1) · '"`UNIQ--vote-00000049-QINU`"' (1)

None (32) · Mild to moderate pain; cough suppression (low-dose). (1)

None (31) · 12.5 mg PO once or twice daily. Titrate gradually: 25-50 mg/day increments every 1-2 days as tolerated. Target dose 300-450 mg/day in divided doses (BID or TID). Most patients stabilize between 200-600 mg/day. Therapeutic plasma level guide: target trough clozapine ≥350 ng/mL. (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (31) · Clozaril 25 mg and 100 mg tablets; FazaClo orally disintegrating tablets (12.5/25/100/150/200 mg); Versacloz oral suspension 50 mg/mL. All brands subject to identical REMS ANC monitoring requirements. Generic tablets widely available. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (31) · 360 mg/day (1) · 900 mg/day (split into BID or TID dosing). Clinical practice rarely exceeds 600 mg/day; seizure risk increases substantially above 600 mg/day and requires consideration of prophylactic anticonvulsant.'"`UNIQ--ref-0000004A-QINU`"' (1)

None (31) · Oral only. No parenteral formulation (a major limitation in acute agitation requiring rapid tranquilization). (1) · PO (only formulation marketed in the US). (1)

None (31) · 30–60 min (PO) (1) · Oral peak plasma 2.5 hours. Clinical antipsychotic response typically emerges over weeks with continued titration; full response assessment requires 3-6 months at adequate therapeutic levels. (1)

None (31) · 4–6 hours (1) · Due to the half-life of 12 hours (wide range), dosing is BID or TID. Once-daily dosing produces higher peak/trough fluctuations and is generally not used except for a single end-of-day dose in stable patients. (1)

None (32) · 2.5–3 hours (1)

None (31) · Approximately 50-60% (oral; subject to first-pass metabolism); food does not significantly affect absorption.'"`UNIQ--ref-0000004C-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (32) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (32) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)